Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

226.46 +8.52 (+3.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 258,577
Open 217.18
Bid (Size) 223.00 (1)
Ask (Size) 275.00 (1)
Prev. Close 217.94
Today's Range 216.27 - 226.70
52wk Range 181.00 - 323.62
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022
From Insulet Corporation
Via Business Wire
5 Analysts Have This to Say About Insulet
Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter: 
Via Benzinga

Performance

YTD
-17.86%
-17.86%
1 Month
+9.20%
+9.20%
3 Month
-18.84%
-18.84%
6 Month
-14.89%
-14.89%
1 Year
-18.71%
-18.71%

More News

Read More
7 Stocks to Buy That Could Make You a Millionaire
Via InvestorPlace
Comparing Fitbits To Medical Devices? This Company Says Things Aren't Even Close
Via Benzinga
4 Analysts Have This to Say About Insulet
Via Benzinga
Expert Ratings for Insulet
Via Benzinga
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
From Insulet Corporation
Via Business Wire
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
From Insulet Corporation
Via Business Wire
Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks
Via Investor's Business Daily
Looking Into Insulet's Return On Capital Employed
Via Benzinga
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
Via Investor's Business Daily
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition
Via InvestorPlace
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
Via InvestorPlace
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Via Benzinga
Recap: Insulet Q1 Earnings
Via Benzinga
Insulet Announces CEO Transition
From Insulet Corporation
Via Business Wire
Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose
From Insulet Corporation
Via Business Wire
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes
Via Benzinga
Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
From Insulet Corporation
Via Business Wire
Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
From Insulet Corporation
Via Business Wire
Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.